Page results
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
Penile plication (Nesbit) procedure post-operative information
-
Information on the insertion of an inflatable penile prosthesis
-
Patient Advice and Liaison Service (PALS)
-
UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Information about the Integrated Women's Service at the RLHIM patient information leaflet
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
File results
-
FOI/2023/0063 - Women who have given birth at the Trust aged 50 or above
-
FOI/2023/0064 - Children's operations cancelled/ delayed for non-clinical reasons from 2018 to 2022
-
FOI/2023/0065 - A&E deaths from 2010 to 2022
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI2017186 Cyber security and cyber attacks
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0242 - Treatment of Haemophilia A